- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01691560
Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity
May 1, 2014 updated by: GlaxoSmithKline
A Proof of Concept Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in the Relief of Dentinal Hypersensitivity
The purpose of this exploratory study is to compare the treatment effect on dentinal hypersensitivity of a tubule occluding dentifrice as measured by Schiff and Tactile sensitivity.
This proof of concept study will compare the test dentifrice with three other treatment groups.
Study Overview
Status
Completed
Conditions
Detailed Description
This will be a single center, eight week, randomized, controlled, examiner blind, four treatment arm, parallel design, stratified (by maximum baseline Schiff Sensitivity Score of the two selected test teeth), exploratory study in participants with at least two sensitive teeth that meet all the criteria at the Screening and Baseline visit.
Participants will be assessed at Baseline, four and eight weeks to monitor clinical efficacy and safety.
Study Type
Interventional
Enrollment (Actual)
140
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Nevada
-
Las Vegas, Nevada, United States, 89121-5466
- BioSci Research America
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants between 18 and 55 years of age, in good general health, with pre-existing self-reported and clinically diagnosed tooth sensitivity are required for entry into the study
- Participants will be required to have at least four teeth with facial/cervical erosion, abrasion and/or gingival recession which respond to qualifying evaporative (air) assessment at the Screening visit and have at least two teeth (incisors, canines or pre-molars) demonstrating signs of sensitivity, measured by qualifying tactile threshold (Yeaple ≤ 20 gram (g)) and evaporative (air) (Schiff Sensitivity Score ≥ 2) assessments at the Baseline visit
Exclusion Criteria:
- Pregnancy: Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
- Breast-feeding: Women who are breast-feeding.
- Medical History: a) Chronic debilitating disease is present b) Chronic disease or other condition is present that is associated with intermittent episodes or constant daily pain, such as arthritis, low back pain, dysmenorrhea, etc.
- Medications: Daily doses of medication, which in the opinion of the investigator, might interfere with the perception of pain, are being taken. Examples of such medications include analgesics, anticonvulsants, antihistamines that cause marked or moderate sedation, sedatives, tranquilizers, mood-altering and anti-inflammatory drugs.
- Dentition Exclusions: a) Sensitive teeth not expected to respond to treatment with an over-the- counter dentifrice in the opinion of the investigator. b) Teeth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns, orthodontic bands, extensive caries or cracked enamel. Sensitive teeth with contributing etiologies other than erosion, abrasion or recession of exposed dentine. c) Dental professional hygiene (includes dental prophylaxis, irrigation, and intensive anti-microbial/anti-biotic therapy) within 14 days of the screening visit. d) Presence of dental implants. e) Lip or tongue piercings. f) Periodontal surgical history within the past 6 months or have been scaled /root planed within the past 3 months.
- Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
- Clinical Study/Experimental Medication: a) Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit b) Previous participation in this study.
- Other: Any subject who in the opinion of the investigator, should not participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 5% calcium sodium phosphosilicate/sodium monofluorophosphate
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate with sodium monofluorophosphate containing 1500 parts per million fluoride (ppmF).
|
Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
|
ACTIVE_COMPARATOR: 0% calcium sodium phosphosilicate/sodium monofluorophosphate
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
|
Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
|
ACTIVE_COMPARATOR: Sodium monofluorophosphate
Dentifrice containing 1000 ppmF as sodium monofluorophosphate
|
Dentifrice containing 1000 ppmF as sodium monofluorophosphate
|
ACTIVE_COMPARATOR: Sodium fluoride
Dentifrice containing 1100 ppmF as sodium fluoride
|
Dentifrice containing 1100 ppmF as sodium fluoride
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 4
Time Frame: Baseline to 4 weeks post administration of study treatment
|
Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale.
According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.
|
Baseline to 4 weeks post administration of study treatment
|
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 4
Time Frame: Baseline to 4 weeks post administration of study treatment
|
Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale.
In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.
|
Baseline to 4 weeks post administration of study treatment
|
Change From Baseline in Evaporative Air Sensitivity Pain Response on Schiff Sensitivity Scale at Week 8
Time Frame: Baseline to 8 weeks post administration of study treatment
|
Response to a constant jet of air applied to hypersensitive teeth was evaluated using a Schiff Sensitivity pain response scale.
According to this analog scale, pain response for each individual stimulated tooth ranged from 0 to 3; 0 - participant does not respond to air stimulation, 1 - participant responds to air stimulus but does not request discontinuation of stimulus, 2 - participant responds to air stimulus and request discontinuation of stimulus, 3 - participant responds to air stimulus, considers stimulus to be painful and request discontinuation of stimulus.
|
Baseline to 8 weeks post administration of study treatment
|
Change From Baseline in Tactile Sensitivity Pain Response (g) at Week 8
Time Frame: Baseline to 8 weeks post administration of study treatment
|
Response to increasing force on hypersensitive teeth was evaluated using a Yeaple Probe pain response scale.
In tactile sensitivity assessment, an increasing force is applied to hypersensitive tooth until a yes response was recorded or the maximum force was reached.
|
Baseline to 8 weeks post administration of study treatment
|
Change From Baseline in Evaporative Air Sensitivity Response on a Visual Rating Scale (VRS) at Week 4
Time Frame: Baseline to 4 weeks post administration of study treatment
|
Participants rated the intensity of their response to the stimulus using a 10 point Visual rating scale of 1 (no Pain) to 10 (intense pain).
|
Baseline to 4 weeks post administration of study treatment
|
Change From Baseline in Evaporative Air Sensitivity Response on VRS at Week 8
Time Frame: Baseline to 8 weeks post administration of study treatment
|
Participants rated the intensity of their response to the stimulus using a 10 point VRS of 1 (no Pain) to 10 (intense pain).
|
Baseline to 8 weeks post administration of study treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2012
Primary Completion (ACTUAL)
November 1, 2012
Study Completion (ACTUAL)
November 1, 2012
Study Registration Dates
First Submitted
September 20, 2012
First Submitted That Met QC Criteria
September 20, 2012
First Posted (ESTIMATE)
September 24, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
May 29, 2014
Last Update Submitted That Met QC Criteria
May 1, 2014
Last Verified
July 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Stomatognathic Diseases
- Tooth Diseases
- Hypersensitivity
- Dentin Sensitivity
- Physiological Effects of Drugs
- Anti-Infective Agents, Local
- Anti-Infective Agents
- Protective Agents
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Cariostatic Agents
- Calcium
- Listerine
- Fluorides
- Sodium Fluoride
- Calcium, Dietary
- Fluorophosphate
Other Study ID Numbers
- RH01426
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dentine Hypersensitivity
-
Sun Yat-sen UniversityCompletedDentine HypersensitivityChina
-
Federal University of UberlandiaCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Fundação de Amparo...UnknownDentin Sensitivity | Dentin Hypersensitivity | Dentine Hypersensitivity | Hypersensitivity DentinBrazil
-
Dow University of Health SciencesCompletedDentine HypersensitivityPakistan
-
Procter and GambleCompletedDentine HypersensitivityUnited States
-
GlaxoSmithKlineCompletedDentine HypersensitivityUnited States
-
GlaxoSmithKlineCompletedDentine HypersensitivityUnited States
-
Federal University of UberlandiaCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Fundação de Amparo...UnknownDentin Sensitivity | Dentin Hypersensitivity | Dentine Hypersensitivity | Hypersensitivity DentinBrazil
-
The University of Hong KongRecruitingDentine HypersensitivityChina
-
Altinbas UniversityCompletedDentine HypersensitivityTurkey
-
Ministry of Health, Saudi ArabiaUnknown
Clinical Trials on 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
-
GlaxoSmithKlineCompletedDentinal HypersensitivityUnited States
-
Government Dental College and Research Institute...Group PharmaCompleted
-
Government Dental College and Research Institute...Group PharmaCompleted
-
Procter and GambleCompleted
-
GlaxoSmithKlineCompleted
-
Procter and GambleCompleted
-
GlaxoSmithKlineCompletedDentine SensitivityUnited Kingdom
-
University of ChileUnknownDentin SensitivityChile
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompleted